Resverlogix

Resverlogix P/FCF

The P/FCF (Price-to-Free-Cash-Flow Ratio) of Resverlogix (RVX.TO) as of Oct 25, 2026 is -5.37. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was -6.52 — a change of -17.72% (higher).

P/FCF

-5.37

YoY

-17.72%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of Resverlogix is 2025 -5.37 . P/FCF (Price-to-Free-Cash-Flow Ratio) of Resverlogix was 2024 -6.52 . It decreases by -17.72% higher compared to the previous year.

The Resverlogix P/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/FCF
Date
P/FCF
Jan 1, 2018
-0.41 USD
Jan 1, 2019
-1.12 USD
Jan 1, 2020
-4,540.72 USD
Jan 1, 2021
-2.25 USD
Jan 1, 2022
-7.12 USD
Jan 1, 2023
-9.60 USD
Jan 1, 2024
-6.52 USD
Jan 1, 2025
-5.37 USD
The Resverlogix P/FCF history
YEARP/FCFYoY
-5.37-17.72%
-6.52-32.08%
-9.60+34.83%
-7.12+216.32%
-2.25-99.95%
-4,540.72+404,136.52%
-1.12+177.17%
-0.41-48.10%
-0.78-9.51%
-0.86-4.38%
-0.90-53.59%
-1.94—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Resverlogix Stock analysis

What does Resverlogix do? Resverlogix Corp is a biopharmaceutical company based in Canada that specializes in the research and development of innovative therapies for cardiovascular diseases. It was founded in 2001 by Dr. Donald J. McCaffrey and has been listed on the Toronto Stock Exchange since 2006. The company focuses on the development of synthetic molecules with the same potential as Resveratrol, a natural compound found in red grapes and wine, for the treatment of cardiovascular diseases. Resverlogix Corp follows an innovative business model that involves identifying disease-causing factors and developing targeted molecules to influence them, with the goal of developing effective therapies for patients with cardiovascular diseases. The company specializes in the development of therapeutic agents for atherosclerosis and diabetic nephropathy, and currently has two main products in clinical development: Apabetalone for the treatment of atherosclerosis and BAC25 for diabetic nephropathy. Apabetalone acts directly on the genome of cells and influences the gene expression of proteins relevant to the development of atherosclerosis, while BAC25 targets glucose and lipid metabolism in the kidney to slow down or prevent the development of diabetic nephropathy. Overall, Resverlogix Corp is a biopharmaceutical company focused on innovative therapies for cardiovascular diseases, with a business model based on identifying disease-causing factors and developing synthetic molecules to target them. Resverlogix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Resverlogix stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of Resverlogix is -5.37 in 2025.

P/FCF (Price-to-Free-Cash-Flow Ratio) of Resverlogix changed from -6.52 to -5.37, representing a -17.72% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/FCF (Price-to-Free-Cash-Flow Ratio) Resverlogix since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Free-Cash-Flow ratio measures how much investors pay for each unit of free cash flow. A lower ratio may indicate better value.

P/FCF = Market Capitalization / Free Cash Flow

To evaluate P/FCF (Price-to-Free-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/FCF (Price-to-Free-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/FCF (Price-to-Free-Cash-Flow Ratio)'s Resverlogix with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Resverlogix

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Resverlogix